Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
31 studies found for:    aptamer
Show Display Options
Rank Status Study
1 Completed A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: ARC1905
2 Completed
Has Results
A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030 plus Lucentis;   Drug: Lucentis
3 Completed A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
Condition: Idiopathic Polypoidal Choroidal Vasculopathy
Intervention: Drug: Zimura
4 Recruiting A Phase 2/3 Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura® (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Conditions: Geographic Atrophy;   Macular Degeneration
Interventions: Drug: Zimura®;   Drug: Sham
5 Completed ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: ARC1905
6 Completed A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: E10030
7 Completed Phase II/III Study of Anti-VEGF in Neovascular AMD
Conditions: Macular Degeneration;   Choroidal Neovascularization
Intervention: Drug: EYE001 anti-VEGF aptamer
8 Recruiting Molecular Biosensors for Detection of Bladder Cancer
Condition: Urinary Bladder Neoplasms
Intervention:
9 Completed Safety and Dosing Evaluation of REG1 Anticoagulation System
Condition: Healthy
Intervention: Drug: REG1
10 Terminated An 18 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
Condition: Age-Related Macular Degeneration
Interventions: Drug: Fovista®;   Drug: bevacizumab;   Drug: ranibizumab;   Drug: aflibercept
11 Completed EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
Condition: Hippel-Lindau Disease
Intervention: Drug: EYE001
12 Completed Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
Condition: Age-Related Macular Degeneration
Intervention: Drug: pegaptanib sodium (Macugen)
13 Terminated A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: ranibizumab;   Drug: E10030 sham intravitreal injection
14 Terminated A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: ranibizumab;   Drug: E10030 sham intravitreal injection
15 Completed A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
Condition: Age-Related Macular Degeneration
Intervention: Drug: Pegaptanib sodium
16 Terminated A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: Pegaptanib sodium
17 Active, not recruiting A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: bevacizumab or aflibercept;   Drug: E10030 sham intravitreal injection
18 Completed Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula
Condition: Diabetic Macular Edema
Intervention: Drug: pegaptanib sodium (Macugen)
19 Active, not recruiting An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration
Condition: Neovascular Age-Related Macular Degeneration
Interventions: Drug: Fovista™;   Drug: Lucentis®;   Drug: Avastin®;   Drug: Eylea®
20 Withdrawn A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B
Condition: Von Willebrand Disease
Intervention: Drug: ARC1779

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.